We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+0.7%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
+$50.8M
Cap. Flow
+$91.6M
Cap. Flow %
8.41%
Top 10 Hldgs %
59.85%
Holding
90
New
23
Increased
22
Reduced
6
Closed
21

Top Buys

Rank Stock Value
1
NXTC icon
NextCure
NXTC
+$43.7M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$34.6M
3
PTCT icon
PTC Therapeutics
PTCT
+$14.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$12.1M
5
XLRN
Acceleron Pharma
XLRN
+$9.98M

Top Sells

Rank Stock Value
1
CHRS icon
Coherus Oncology
CHRS
+$13.5M
2
AZN icon
AstraZeneca
AZN
+$10.6M
3
ANAB icon
AnaptysBio
ANAB
+$7.16M
4
XNCR icon
Xencor
XNCR
+$6.52M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.43M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
51
Syndax Pharmaceuticals
SNDX
$1.84B
$2.26M 0.21%
242,729
+29,370
+14% +$214K
DCPH
52
PUT
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.26M 0.21%
+100,100
New +$2.34M
ADVM
53
DELISTED
Adverum Biotechnologies
ADVM
$2.23M 0.2%
18,706
+2,782
+17% +$230K
ABBV icon
54
AbbVie
ABBV
$458B
$2.1M 0.19%
+28,911
New +$2.27M
CALA
55
DELISTED
Calithera Biosciences, Inc
CALA
$2.07M 0.19%
+26,492
New +$3.01M
ALNY icon
56
Alnylam Pharmaceuticals
ALNY
$36.3B
$2.02M 0.19%
27,792
-78,824
-74% -$6.05M
RVLP
57
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$2M 0.18%
525,198
+272,109
+108% +$905K
KALA icon
58
KALA BIO
KALA
$11.8M
$1.9M 0.17%
119
-19
-14% -$315K
CLVS
59
DELISTED
Clovis Oncology, Inc.
CLVS
$1.86M 0.17%
125,303
+58,668
+88% +$1.06M
ITCI
60
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.64M 0.15%
+125,955
New +$1.62M
BCRX icon
61
BioCryst Pharmaceuticals
BCRX
$2.37B
$1.62M 0.15%
+426,400
New +$2.57M
ACOR
62
DELISTED
Acorda Therapeutics
ACOR
$1.49M 0.14%
+1,617
New +$1.99M
FTSV
63
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$1.26M 0.12%
+118,803
New +$1.74M
APLS
64
DELISTED
Apellis Pharmaceuticals
APLS
$1.26M 0.12%
49,580
– –
APLT
65
DELISTED
Applied Therapeutics
APLT
$1.17M 0.11%
+142,004
New +$1.34M
AUTL
66
Autolus Therapeutics
AUTL
$386M
$1.06M 0.1%
+65,780
New +$1.47M
PDSB icon
67
PDS Biotechnology
PDSB
$38.1M
$854K 0.08%
142,635
– –
ABBV icon
68
CALL
AbbVie
ABBV
$458B
– –
-150,000
Closed -$12.1M
ANAB icon
69
AnaptysBio
ANAB
$1.6B
– –
-97,948
Closed -$7.16M
AZN icon
70
AstraZeneca
AZN
$263B
– –
-130,789
Closed -$10.6M
BIIB icon
71
CALL
Biogen
BIIB
$29.9B
– –
-40,000
Closed -$9.46M
BPMC
72
DELISTED
Blueprint Medicines
BPMC
– –
-71,866
Closed -$5.75M
FATE icon
73
Fate Therapeutics
FATE
$281M
– –
-203,742
Closed -$3.58M
KYNB
74
Kyntra Bio
KYNB
$28.5M
– –
-2,361
Closed -$3.21M
KYNB
75
PUT
Kyntra Bio
KYNB
$28.5M
– –
-2,000
Closed -$2.72M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2019 Portfolio in Review

As of Q2 2019, Sofinnova Investments held 90 positions worth $1.09B, up 4.9% from $1.04B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments deployed $91.6M of net new capital in Q2 2019, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was NextCure: 210,155 shares worth $37.8M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Coherus Oncology, an estimated $13.5M trimmed.

  • Sofinnova Investments's largest Q2 2019 buy was NextCure: 210,155 shares worth $37.8M.
  • Sofinnova Investments added most to Ascendis Pharma A/S in Q2 2019, an estimated $12.1M increase.
  • Sofinnova Investments's biggest Q2 2019 reduction was Coherus Oncology, cutting an estimated $13.5M.
  • Sofinnova Investments fully exited AstraZeneca in Q2 2019, selling an estimated $10.6M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.09B portfolio in Q2 2019.
  • Sofinnova Investments opened 23 new positions and closed 21 in Q2 2019.
  • Sofinnova Investments's portfolio value rose 4.9% quarter-over-quarter to $1.09B.

Based on Sofinnova Investments's 13F filing for Q2 2019, filed 13 Aug 2019.